;PMID: 11007041
;source_file_728.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:39..149] = [t:39..149]
;2)section:[e:153..241] = [t:153..241]
;3)section:[e:245..372] = [t:245..372]
;4)sentence:[e:376..461] = [t:376..461]
;5)sentence:[e:462..635] = [t:462..635]
;6)sentence:[e:636..764] = [t:636..764]
;7)sentence:[e:766..823] = [t:766..823]
;8)sentence:[e:824..1013] = [t:824..1013]
;9)sentence:[e:1014..1168] = [t:1014..1168]
;10)sentence:[e:1169..1272] = [t:1169..1272]
;11)sentence:[e:1273..1396] = [t:1273..1396]
;12)sentence:[e:1397..1486] = [t:1397..1486]
;13)sentence:[e:1487..1732] = [t:1487..1732]
;14)sentence:[e:1733..1940] = [t:1733..1940]
;15)sentence:[e:1941..2072] = [t:1941..2072]
;16)section:[e:2076..2121] = [t:2076..2121]

;section 0 Span:0..34
;Mod Pathol  2000 Sep;13(9):1005-13
(SEC
  (FRAG (DT:[0..3] Mod) (NNP:[4..10] Pathol) (CD:[12..16] 2000)
        (.:[17..24] Sep;13-LRB-) (CD:[24..25] 9) (-RRB-:[25..26] -RRB-)
        (CD:[26..31] :1005) (::[31..32] -) (CD:[32..34] 13)))

;sentence 1 Span:39..149
;Beta-catenin in soft tissue sarcomas: expression is related to proliferative 
;activity in high-grade sarcomas.
;[39..51]:gene-protein:"Beta-catenin"
;[55..75]:malignancy:"soft tissue sarcomas"
;[129..148]:malignancy:"high-grade sarcomas"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[39..51] Beta-catenin))
      (PP-LOC (IN:[52..54] in)
        (NP
          (NML (JJ:[55..59] soft) (NN:[60..66] tissue))
          (NNS:[67..75] sarcomas))))
    (::[75..76] :)
    (S
      (NP-SBJ-1 (NN:[77..87] expression))
      (VP (VBZ:[88..90] is)
        (VP (VBN:[91..98] related)
          (NP-1 (-NONE-:[98..98] *))
          (PP-CLR (TO:[99..101] to)
            (NP (JJ:[102..115] proliferative) (NN:[117..125] activity)))
          (PP (IN:[126..128] in)
            (NP
              (NML (JJ:[129..133] high) (HYPH:[133..134] -)
                   (NN:[134..139] grade))
              (NNS:[140..148] sarcomas))))))
    (.:[148..149] .)))

;section 2 Span:153..241
;Kuhnen C, Herter P, Muller O, Muehlberger T, Krause L, Homann H, Steinau HU, 
;Muller KM.
(SEC
  (FRAG (NNP:[153..159] Kuhnen) (NNP:[160..161] C) (,:[161..162] ,)
        (NNP:[163..169] Herter) (NNP:[170..171] P) (,:[171..172] ,)
        (NNP:[173..179] Muller) (NNP:[180..181] O) (,:[181..182] ,)
        (NNP:[183..194] Muehlberger) (NNP:[195..196] T) (,:[196..197] ,)
        (NNP:[198..204] Krause) (NNP:[205..207] L,) (NNP:[208..214] Homann)
        (NNP:[215..216] H) (,:[216..217] ,) (NNP:[218..225] Steinau)
        (NNP:[226..228] HU) (,:[228..229] ,) (NNP:[231..237] Muller)
        (NNP:[238..240] KM) (.:[240..241] .)))

;section 3 Span:245..372
;Institute for Pathology, Limb Tumor Registry, University Hospital
;Bergmannsheil,  Bochum, Germany. patho-bhl@ruhr-uni-bochum.de
(SEC
  (FRAG (NNP:[245..254] Institute) (IN:[255..258] for)
        (NNP:[259..268] Pathology) (,:[268..269] ,) (NNP:[270..274] Limb)
        (NNP:[275..280] Tumor) (NNP:[281..289] Registry) (,:[289..290] ,)
        (NNP:[291..301] University) (NNP:[302..310] Hospital)
        (NNP:[311..324] Bergmannsheil) (,:[324..325] ,) (NNP:[327..333] Bochum)
        (,:[333..334] ,) (NNP:[335..342] Germany) (.:[342..343] .)
        (VB:[344..349] patho) (::[349..350] -) (SYM:[350..358] bhl@ruhr)
        (::[358..359] -) (SYM:[359..362] uni) (::[362..363] -)
        (VBN:[363..369] bochum) (.:[369..372] .de)))

;sentence 4 Span:376..461
;Besides its role in cell adhesion, beta-catenin exerts a function as an 
;oncoprotein.
;[411..423]:gene-protein:"beta-catenin"
;[449..460]:gene-protein:"oncoprotein"
(SENT
  (S
    (PP (IN:[376..383] Besides)
      (NP
        (NP (PRP$:[384..387] its) (NN:[388..392] role))
        (PP (IN:[393..395] in)
          (NP (NN:[396..400] cell) (NN:[401..409] adhesion)))))
    (,:[409..410] ,)
    (NP-SBJ (NN:[411..423] beta-catenin))
    (VP (VBZ:[424..430] exerts)
      (NP
        (NP (DT:[431..432] a) (NN:[433..441] function))
        (PP (IN:[442..444] as)
          (NP (DT:[445..447] an) (NN:[449..460] oncoprotein)))))
    (.:[460..461] .)))

;sentence 5 Span:462..635
;The aim of this study was the characterization of its expression,  possible
;mutation, and the assessment of beta-catenin as a prognostic indicator  for
;soft tissue sarcomas.
;[570..582]:gene-protein:"beta-catenin"
;[614..634]:malignancy:"soft tissue sarcomas"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[462..465] The) (NN:[466..469] aim))
      (PP (IN:[470..472] of)
        (NP (DT:[473..477] this) (NN:[478..483] study))))
    (VP (VBD:[484..487] was)
      (NP-PRD
        (NP
          (NP (DT:[488..491] the) (NN:[492..508] characterization))
          (PP (IN:[509..511] of)
            (NP
              (NP (PRP$:[512..515] its) (NN:[516..526] expression))
              (,:[526..527] ,)
              (NP (JJ:[529..537] possible) (NN:[538..546] mutation)))))
        (,:[546..547] ,) (CC:[548..551] and)
        (NP
          (NP (DT:[552..555] the) (NN:[556..566] assessment))
          (PP (IN:[567..569] of)
            (NP
              (NP (NN:[570..582] beta-catenin))
              (PP (IN:[583..585] as)
                (NP
                  (NP (DT:[586..587] a) (JJ:[588..598] prognostic)
                      (NN:[599..608] indicator))
                  (PP (IN:[610..613] for)
                    (NP
                      (NML (JJ:[614..618] soft) (NN:[619..625] tissue))
                      (NNS:[626..634] sarcomas))))))))))
    (.:[634..635] .)))

;sentence 6 Span:636..764
;A total of 115 soft tissue sarcomas were analyzed  using
;immunohistochemistry, immunogold-electron microscopy, and DNA analysis.
;[651..671]:malignancy:"soft tissue sarcomas"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[636..637] A) (NN:[638..643] total))
      (PP (IN:[644..646] of)
        (NP (CD:[647..650] 115)
          
          (NML (JJ:[651..655] soft) (NN:[656..662] tissue))
          (NNS:[663..671] sarcomas))))
    (VP (VBD:[672..676] were)
      (VP (VBN:[677..685] analyzed)
        (NP-1 (-NONE-:[685..685] *))
        (S-MNR
          (NP-SBJ (-NONE-:[685..685] *))
          (VP (VBG:[687..692] using)
            (NP
              (NP (NN:[693..713] immunohistochemistry))
              (,:[713..714] ,)
              (NP (NN:[715..725] immunogold) (HYPH:[725..726] -)
                  (NN:[726..734] electron) (NN:[735..745] microscopy))
              (,:[745..746] ,) (CC:[747..750] and)
              (NP (NN:[751..754] DNA) (NN:[755..763] analysis)))))))
    (.:[763..764] .)))

;sentence 7 Span:766..823
;Information from 56 patients was available for follow-up.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[766..777] Information))
      (PP (IN:[778..782] from)
        (NP (CD:[783..785] 56) (NNS:[786..794] patients))))
    (VP (VBD:[795..798] was)
      (ADJP-PRD (JJ:[799..808] available)
        (PP (IN:[809..812] for)
          (NP (VB:[813..819] follow) (HYPH:[819..820] -) (RP:[820..822] up)))))
    (.:[822..823] .)))

;sentence 8 Span:824..1013
;A statistically  significant correlation was found between intracellular
;distribution of  beta-catenin and the proliferative activity (MIB-1
;expression) in high-grade  sarcomas (P = .0008).
;[914..926]:gene-protein:"beta-catenin"
;[959..964]:gene-rna:"MIB-1"
;[980..1000]:malignancy:"high-grade  sarcomas"
(SENT
  (S
    (NP-SBJ-1 (DT:[824..825] A)
      (ADJP (RB:[826..839] statistically) (JJ:[841..852] significant))
      (NN:[853..864] correlation))
    (VP (VBD:[865..868] was)
      (VP (VBN:[869..874] found)
        (NP-1 (-NONE-:[874..874] *))
        (PP (IN:[875..882] between)
          (NP
            (NP
              (NP (JJ:[883..896] intracellular) (NN:[897..909] distribution))
              (PP (IN:[910..912] of)
                (NP (NN:[914..926] beta-catenin))))
            (CC:[927..930] and)
            (NP (DT:[931..934] the) (JJ:[935..948] proliferative)
                (NN:[949..957] activity)
              (PRN (-LRB-:[958..959] -LRB-)
                (NP (NN:[959..964] MIB-1) (NN:[965..975] expression))
                (-RRB-:[975..976] -RRB-)))))
        (PP-LOC (IN:[977..979] in)
          (NP (JJ:[980..984] high) (HYPH:[984..985] -) (NN:[985..990] grade)
              (NNS:[992..1000] sarcomas)))
        (PRN (-LRB-:[1001..1002] -LRB-)
          (S
            (NP-SBJ (NN:[1002..1003] P))
            (VP (SYM:[1004..1005] =)
              (NP (CD:[1006..1011] .0008))))
          (-RRB-:[1011..1012] -RRB-))))
    (.:[1012..1013] .)))

;sentence 9 Span:1014..1168
;Beta-catenin was identified with intracytoplasmic and  nuclear accumulation,
;showing additional membranous staining in sarcomas with  epithelioid
;pattern.
;[1014..1026]:gene-protein:"Beta-catenin"
;[1133..1141]:malignancy:"sarcomas"
(SENT
  (S
    (NP-SBJ-2 (NN:[1014..1026] Beta-catenin))
    (VP (VBD:[1027..1030] was)
      (VP (VBN:[1031..1041] identified)
        (NP-2 (-NONE-:[1041..1041] *))
        (PP-CLR (IN:[1042..1046] with)
          (NP
            (NP (JJ:[1047..1063] intracytoplasmic)
              (NML-1 (-NONE-:[1063..1063] *P*)))
            (CC:[1064..1067] and)
            (NP (JJ:[1069..1076] nuclear)
              (NML-1 (NN:[1077..1089] accumulation)))))
        (,:[1089..1090] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1090..1090] *))
          (VP (VBG:[1091..1098] showing)
            (NP (JJ:[1099..1109] additional) (JJ:[1110..1120] membranous)
                (NN:[1121..1129] staining))
            (PP-LOC (IN:[1130..1132] in)
              (NP
                (NP (NNS:[1133..1141] sarcomas))
                (PP (IN:[1142..1146] with)
                  (NP (JJ:[1148..1159] epithelioid) (NN:[1160..1167] pattern)))))))))
    (.:[1167..1168] .)))

;sentence 10 Span:1169..1272
;Ultrastructurally, a colocalization between beta-catenin  and nuclear
;heterochromatin was demonstrated.
;[1213..1225]:gene-protein:"beta-catenin"
(SENT
  (S
    (ADVP (RB:[1169..1186] Ultrastructurally))
    (,:[1186..1187] ,)
    (NP-SBJ-1
      (NP (DT:[1188..1189] a) (NN:[1190..1204] colocalization))
      (PP (IN:[1205..1212] between)
        (NP
          (NP (NN:[1213..1225] beta-catenin))
          (CC:[1227..1230] and)
          (NP (JJ:[1231..1238] nuclear) (NN:[1239..1254] heterochromatin)))))
    (VP (VBD:[1255..1258] was)
      (VP (VBN:[1259..1271] demonstrated)
        (NP-1 (-NONE-:[1271..1271] *))))
    (.:[1271..1272] .)))

;sentence 11 Span:1273..1396
;In 22 analyzed tumors, only one  (yet undescribed) mutation of the
;beta-catenin gene (C-A transversion) could be  detected.
;[1288..1294]:malignancy:"tumors"
;[1324..1332]:variation-event:"mutation"
;[1340..1352]:gene-rna:"beta-catenin"
;[1359..1360]:variation-state-original:"C"
;[1361..1362]:variation-state-altered:"A"
;[1363..1375]:variation-type:"transversion"
(SENT
  (S
    (PP-LOC (IN:[1273..1275] In)
      (NP (CD:[1276..1278] 22) (VBN:[1279..1287] analyzed)
          (NNS:[1288..1294] tumors)))
    (,:[1294..1295] ,)
    (NP-SBJ-1
      (NP (RB:[1296..1300] only) (CD:[1301..1304] one)
        (PRN (-LRB-:[1306..1307] -LRB-)
          (ADJP (RB:[1307..1310] yet) (JJ:[1311..1322] undescribed))
          (-RRB-:[1322..1323] -RRB-))
        (NN:[1324..1332] mutation))
      (PP (IN:[1333..1335] of)
        (NP (DT:[1336..1339] the) (NN:[1340..1352] beta-catenin)
            (NN:[1353..1357] gene)))
      (PRN (-LRB-:[1358..1359] -LRB-)
        (NP
          (NML
            (NML (NN:[1359..1360] C))
            (PP (HYPH:[1360..1361] -)
              (NP (NN:[1361..1362] A))))
          (NN:[1363..1375] transversion))
        (-RRB-:[1375..1376] -RRB-)))
    (VP (MD:[1377..1382] could)
      (VP (VB:[1383..1385] be)
        (VP (VBN:[1387..1395] detected)
          (NP-1 (-NONE-:[1395..1395] *)))))
    (.:[1395..1396] .)))

;sentence 12 Span:1397..1486
;Prognostic validity of the cellular expression of beta-catenin,  however, was
;not proven.
;[1447..1459]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1397..1407] Prognostic) (NN:[1408..1416] validity))
      (PP (IN:[1417..1419] of)
        (NP
          (NP (DT:[1420..1423] the) (JJ:[1424..1432] cellular)
              (NN:[1433..1443] expression))
          (PP (IN:[1444..1446] of)
            (NP (NN:[1447..1459] beta-catenin))))))
    (,:[1459..1460] ,)
    (ADVP (RB:[1462..1469] however))
    (,:[1469..1470] ,)
    (VP (VBD:[1471..1474] was) (RB:[1475..1478] not)
      (VP (VBN:[1479..1485] proven)
        (NP-1 (-NONE-:[1485..1485] *))))
    (.:[1485..1486] .)))

;sentence 13 Span:1487..1732
;Apart from its membranous function as an effective  molecule for
;cell-adhesion in sarcomas with epithelioid pattern, beta-catenin  may act as
;an oncoprotein in sarcomas with intracytoplasmic and nuclear  localization
;with binding to nuclear DNA.
;[1569..1577]:malignancy:"sarcomas"
;[1604..1616]:gene-protein:"beta-catenin"
;[1632..1643]:gene-protein:"oncoprotein"
;[1647..1655]:malignancy:"sarcomas"
(SENT
  (S
    (PP (IN:[1487..1492] Apart)
      (PP (IN:[1493..1497] from)
        (NP
          (NP (PRP$:[1498..1501] its) (JJ:[1502..1512] membranous)
              (NN:[1513..1521] function))
          (PP (IN:[1522..1524] as)
            (NP
              (NP (DT:[1525..1527] an) (JJ:[1528..1537] effective)
                  (NN:[1539..1547] molecule))
              (PP (IN:[1548..1551] for)
                (NP
                  (NP (NN:[1552..1556] cell) (HYPH:[1556..1557] -)
                      (NN:[1557..1565] adhesion))
                  (PP-LOC (IN:[1566..1568] in)
                    (NP
                      (NP (NNS:[1569..1577] sarcomas))
                      (PP (IN:[1578..1582] with)
                        (NP (JJ:[1583..1594] epithelioid)
                            (NN:[1595..1602] pattern))))))))))))
    (,:[1602..1603] ,)
    (NP-SBJ (NN:[1604..1616] beta-catenin))
    (VP (MD:[1618..1621] may)
      (VP (VB:[1622..1625] act)
        (PP (IN:[1626..1628] as)
          (NP (DT:[1629..1631] an) (NN:[1632..1643] oncoprotein)))
        (PP (IN:[1644..1646] in)
          (NP
            (NP (NNS:[1647..1655] sarcomas))
            (PP (IN:[1656..1660] with)
              (NP
                (NP (JJ:[1661..1677] intracytoplasmic)
                  (NML-1 (-NONE-:[1677..1677] *P*)))
                (CC:[1678..1681] and)
                (NP (JJ:[1682..1689] nuclear)
                  (NML-1 (NN:[1691..1703] localization)))))))
        (PP (IN:[1704..1708] with)
          (NP
            (NP (NN:[1709..1716] binding))
            (PP (TO:[1717..1719] to)
              (NP (JJ:[1720..1727] nuclear) (NN:[1728..1731] DNA)))))))
    (.:[1731..1732] .)))

;sentence 14 Span:1733..1940
;A previously discussed stimulation of  cell proliferation caused by an
;increased beta-catenin level can also be  postulated for high-grade soft
;tissue sarcomas in correlation with the rate of  proliferation.
;[1814..1826]:gene-protein:"beta-catenin"
;[1861..1892]:malignancy:"high-grade soft tissue sarcomas"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (DT:[1733..1734] A)
          (ADJP (RB:[1735..1745] previously) (VBN:[1746..1755] discussed))
          (NN:[1756..1767] stimulation))
        (PP (IN:[1768..1770] of)
          (NP (NN:[1772..1776] cell) (NN:[1777..1790] proliferation))))
      (VP (VBN:[1791..1797] caused)
        (NP-SBJ (-NONE-:[1797..1797] *))
        (PP (IN:[1798..1800] by)
          (NP-LGS (DT:[1801..1803] an) (VBN:[1804..1813] increased)
                  (NN:[1814..1826] beta-catenin) (NN:[1827..1832] level)))))
    (VP (MD:[1833..1836] can)
      (ADVP (RB:[1837..1841] also))
      (VP (VB:[1842..1844] be)
        (VP (VBN:[1846..1856] postulated)
          (NP-1 (-NONE-:[1856..1856] *))
          (PP (IN:[1857..1860] for)
            (NP
              (NML (JJ:[1861..1865] high) (HYPH:[1865..1866] -)
                   (NN:[1866..1871] grade))
              (NML (JJ:[1872..1876] soft) (NN:[1877..1883] tissue))
              (NNS:[1884..1892] sarcomas)))
          (PP (IN:[1893..1895] in)
            (NP
              (NP (NN:[1896..1907] correlation))
              (PP (IN:[1908..1912] with)
                (NP
                  (NP (DT:[1913..1916] the) (NN:[1917..1921] rate))
                  (PP (IN:[1922..1924] of)
                    (NP (NN:[1926..1939] proliferation))))))))))
    (.:[1939..1940] .)))

;sentence 15 Span:1941..2072
;Mutations of the beta-catenin gene are probably of lesser  importance for the
;accumulation of beta-catenin in soft tissue sarcomas.
;[1958..1970]:gene-rna:"beta-catenin"
;[2035..2047]:gene-protein:"beta-catenin"
;[2051..2071]:malignancy:"soft tissue sarcomas"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1941..1950] Mutations))
      (PP (IN:[1951..1953] of)
        (NP (DT:[1954..1957] the) (NN:[1958..1970] beta-catenin)
            (NN:[1971..1975] gene))))
    (VP (VBP:[1976..1979] are)
      (ADVP (RB:[1980..1988] probably))
      (PP-PRD (IN:[1989..1991] of)
        (NP
          (NP (JJR:[1992..1998] lesser) (NN:[2000..2010] importance))
          (PP (IN:[2011..2014] for)
            (NP
              (NP (DT:[2015..2018] the) (NN:[2019..2031] accumulation))
              (PP (IN:[2032..2034] of)
                (NP (NN:[2035..2047] beta-catenin)))
              (PP-LOC (IN:[2048..2050] in)
                (NP
                  (NML (JJ:[2051..2055] soft) (NN:[2056..2062] tissue))
                  (NNS:[2063..2071] sarcomas))))))))
    (.:[2071..2072] .)))

;section 16 Span:2076..2121
;PMID: 11007041 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2076..2080] PMID) (::[2080..2081] :) (CD:[2082..2090] 11007041)
        (NN:[2091..2092] -LSB-) (NNP:[2092..2098] PubMed) (::[2099..2100] -)
        (NN:[2101..2108] indexed) (IN:[2109..2112] for)
        (NNP:[2113..2121] MEDLINE-RSB-)))
